Criteria for the clinical use of Intravenous Immunoglobulin in Australia - Second Edition
Term | Page |
---|---|
Behçet’s disease | 215 |
bibliography | 225–6 |
Biotext Pty Ltd | 39, 234, 248–9 |
Blood and Blood Products Committee | 12, 31 |
blood stewardship principles | 231–2 |
bronchiectasis | 113 |
bullous pemphigoid | 126–7 |
Term | Page |
---|---|
dermatomyositis | 73-8 |
desmoglein 1: | 166 |
Devic disease | 193 |
diabetic amyotrophy | 194 |
diabetic lumbosacral radiculoplexus neuropathy | 194 |
diabetic proximal neuropathy | 194 |
Diamond Blackfan syndrome | 215 |
diffuse macular rash | 179 |
diplopia | 92 |
disclaimer | ii |
discussion paper | 237 |
dosage regimens | 3, 44 |
dysphagia | 74-5, 92 |
Term | Page |
---|---|
eczema | 214 |
end stage renal disease | 153 |
epidermolysis bullosa acquisita | 194 |
epilepsy | 194 |
erythematous macular rash | 179 |
European Medicines Agency | 26 |
Evans syndrome | 133-5 |
evidence, assessment of | 39-40 |
evidence of benefit categories | 40, 241 |
Evidence Statement Form | 39-40, 249 |
Evidence-based practice workbook | 39, 248 |
exclusion criteria | 41 |
executive summary | 11-14 |
experimental allergic encephalomyelitis | 115 |
exposure draft | 239-40 |
Term | Page |
---|---|
female infertility | 215 |
filtration of viruses | 27 |
foeto-maternal/neonatal alloimmune thrombocytopenia | 136-40 |
funding for blood sector | 16-17 |
funding policy statement | 228-9 |
Term | Page |
---|---|
gangrene | 178 |
glomerulonephritis | 215 |
glossary of terms | 222-4 |
governance of blood products supply | 17-18 |
Graves ophthalmopathy | 195 |
Guillain-Barré syndrome | 62-5 |
Term | Page |
---|---|
haemolytic disease of the newborn | 196 |
haemolytic transfusion reaction | 197 |
haemolytic uraemic syndrome | 215 |
haemophagocytic syndrome | 141-3 |
haemotopoietic stem cell transplantation | 107 |
Hashimoto encephalopathy | 197 |
Henoch–Schonlein purpura | 215 |
HIV-related conditions | 67, 70, 215 |
How to review the evidence | 39, 248 |
hyperlordosis | 99 |
hypotension | 178-9 |
Term | Page |
---|---|
iatrogenic immunodeficiency | 106–9 |
idiopathic dilated cardiomyopathy | 215 |
idiopathic thrombocytopenic purpura | 66–72, 144–7 |
IgA nephritis | 215 |
IgM paraproteinaemic neuropathy | 148-51 |
immune thrombocytopenic purpura | 104 |
immunoadsorption, responses to | 58 |
immunodeficiency, evidence of | 42-3 |
immunoglobulin replacement therapy | 105 |
immunoglobulins, see intravenous immunoglobulin | |
immunomodulation therapy | 43, 105 |
inclusion body myositis | 73–8 |
index of conditions | 6–10 |
individual experts | 5, 245 |
inflammatory myopathies | 73–8 |
international supply and demand | 30, 33–4 |
intravenous immunoglobulin | |
cost of | 32 |
definition of | 16 |
guidelines for use of | 2 |
imports of | 11, 21 |
in Australia | 28 |
manufacture of | 11, 20-1 |
production of | 24-8 |
supply and demand | 30-4 |
IVIg, see intravenous immunoglobulin | |
IVIg Working Party | 235-7 |
Term | Page |
---|---|
Jurisdictional Blood Committee | 4, 13, 18, 37, 235–7, 252 |
jurisdictional direct orders | 17, 21–2 |
Term | Page |
---|---|
Kawasaki disease | 79–82 |
kidney transplantation | 104, 152–7 |
Term | Page |
---|---|
Lambert–Eaton myasthenic syndrome | 83–6 |
Landau–Keffner syndrome | 194 |
Lennox–Gastaut syndrome | 194 |
level of evidence categories | 40, 241 |
life-threatening haemorrhage | 69, 145 |
limbic encephalitis | 198, 200 |
linear IgA disease | 215 |
literature reviews | 36, 234–5, 242 |
lupus cerebritis | 215 |
lupus nephritis | 215 |
Lyell syndrome | 173-6 |
lymphoblastic leukaemia | 185 |
lymphoproliferative disorder | 49 |
Term | Page |
---|---|
maintenance of criteria | 44 |
microscopic polyangiitis | 119 |
miscellaneous hypogammaglobulinaemia | 56 |
Moersch–Woltman syndrome | 99-101 |
monoclonal gammopathy | 148 |
motor neuron disease | 215 |
mucocutaneous lymph node syndrome | 79-82 |
mucous membrane pemphigoid | 129-32 |
multifocal motor neuropathy | 87-91 |
multiple myeloma | 49 |
multiple sclerosis | 158-63 |
myalgic encephalomyelitis | 215 |
myasthenia gravis | 92-5 |
myeloblastic leukaemia | 185 |
myocarditis, in children | 198 |
Term | Page |
---|---|
narcolepsy | 216 |
National Blood Agreement | 16-17 |
National Blood Arrangements | 2 |
National Blood Authority | 18, 31, 37 |
National Blood Supply | 21–2 |
National Health and Medical Research Council | 39–40 |
National IVIg Criteria Review Working Group | 4–5, 38, 235–7, 244–53 |
National Stewardship Expectations | 230–2 |
National Workshop | 233 |
neonatal conditions, see also paediatric conditions; pregnancy-related conditions | |
alloimmune thrombocytopenia | 136–40 |
haemochromatosis | 96-8 |
haemolytic disease of the newborn | 196 |
lupus | 186 |
nephrotic syndrome | 216 |
neuromyelitis optica | 193 |
non-Hodgkin lymphoma | 48 |
nonparaneoplastic limbic encephalitis | 198 |
Term | Page |
---|---|
obsessive compulsive disorders | 216 |
off-label medical use | 26-7 |
opsoclonus-myoclonus ataxia | 164-5 |
orphan drug program | 27 |
overseas suppliers of IVIg | 11, 21 |
Term | Page |
---|---|
qualifying criteria | 41 |
Term | Page |
---|---|
Rasmussen syndrome | 206 |
recurrent bacterial infections | 42, 106, 111 |
recurrent foetal loss | 216 |
Red Cross Blood Service | 30 |
refractory acute ITP | 68 |
rejection of transplanted organs | 152 |
replacement therapy | 42-3 |
research priorities | 44 |
review criteria | 41 |
Review of Australia’s plasma fractionation arrangements | 21 |
Review of the Australian blood banking and plasma product sector | 20-1 |
Review of the cost effectiveness of IVIg in Australia | 235 |
Review of the use and supply of intravenous immunoglobulins in Australia | 20 |
rheumatoid arthritis | 216 |
rifampicin | 166 |
Term | Page |
---|---|
scleromyxedema | 207 |
secondary hypogammaglobulinaemia | 50, 106–9 |
secretariat support | 246 |
sepsis | 216-17 |
sickle cell disease | 217 |
siderosis | 97 |
Sjogren syndrome | 207 |
soft tissue necrosis | 178 |
solid organ transplantation (other than kidney) | 50, 208 |
specific antibody deficiency | 56, 110–14 |
Standing Council on Health | 17–18 |
Standing Offer for IVIg imports | 17, 21–2, 31 |
staphylococcal toxic shock syndrome | 177–82 |
Statement on national stewardship expectations for the supply of blood and blood products | 17-18 |
stem cell transplantation | 50 |
steroid-responsive encephalopathy associated with autoimmune thyroiditis | 197 |
Stevens–Johnson syndrome | 173-6 |
stiff person syndrome | 99-101 |
stretococcal infections | |
paediatric autoimmune neuropsychiatric disorder | 199 |
toxic shock syndrome | 177–82 |
submissions to review | 246–7 |
Susac syndrome | 209 |
Sydney Health Projects Group | 234, 243 |
systematic review | 248–9 |
systemic capillary leak syndrome | 210–11 |
systemic lupus erythematosus | 217 |
Term | Page |
---|---|
Therapeutic Goods Administration | 2, 12, 19, 25–7 |
thiol-containing compounds | 166 |
thromobocytopenia | 66-7 |
toxic epidermal necrolysis | 173-6 |
toxic shock syndrome | 177-82 |
transfusion medicine services | 22 |
Transmissible Spongiform Encephalopathies Advisory Committee | 27-8 |
transplants | 50, 208 |
Term | Page |
---|---|
ulcerative colitis | 217 |
Term | Page |
---|---|
veno-occlusive disease | 49 |
viral pathogens, destroying | 24–5, 27–8 |
Term | Page |
---|---|
Wegener granulomatosis | 119 |
Wiskott Aldrich syndrome | 55 |
working party | 4–5, 38, 235–7, 244–53 |